Affimed Email Format

Biotechnology ResearchBaden-württemberg, Germany11-50 Employees

Affimed N.V. is a clinical-stage biotechnology company headquartered in Mannheim, Baden-Württemberg, Germany, focused on immuno-oncology. It develops innate cell engagers, bispecific antibodies that recruit and activate innate immune cells—such as natural killer cells and macrophages—to attack tumor cells. These molecules are generated on the ROCK platform and are explored as standalone therapies and in combination with other immune therapies across hematologic and solid tumors. 

The company’s clinical programs target three areas: AFM13 for CD30-positive lymphomas, AFM24 for EGFR-expressing solid tumors, and AFM28 for CD123-expressing AML. In 2025 Affimed highlighted data from its programs, including abstracts accepted for ASCO and AACR and a post-hoc analysis indicating higher AFM24 exposure is associated with higher response rates and longer progression-free survival in NSCLC, informing dose optimization and combination strategies.

Sign up for free to view info

Company overview Employee directory